| Ytd | 89.77% | |
| 1y | 85.73% |
| Open | 14.84 | Prev Close | 14.84 | Low | 14.84 | High | 14.84 | Mkt Cap | 2.20B |
| Vol | 38.51M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -5.17 |
| Beta | 1.26 | Short Ratio | 0.74 | Inst. Own | 103.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 30.38 |
ETNB News
The market continues to trade deeper in overbought territory based on most traditional valuation met
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde &
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that ma
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Sm
On Thursday, Roche Holdings AG RHHBY agreed to acquire 89bio, Inc. ETNB for $2.4 billion. 89Bio is a
U.S. stock futures advanced on Thursday following Wednesday's mixed moves. Futures of major benc
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Roche has agreed to acquire American biotech 89bio in a transaction worth up to $3.5 billion, as it
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 89bio (Nasdaq: ETNB) for possible breach
The deal seeks to strengthen the drugmaker's pipeline by adding an experimental drug for an obesity
Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cas
89bio, Inc. (NASDAQ:ETNB ) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT C
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ET
89bio, Inc. (NASDAQ:ETNB ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT
Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those
89bio (ETNB) Q2 R&D Jumps 131%
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some bi
Tuesday's session saw 211 companies set new 52-week lows.
On Friday, 213 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
On Monday, 466 companies hit new 52-week lows.
During Friday's morning session, 234 stocks hit new 52-week lows.
During Tuesday's session, 454 stocks hit new 52-week lows.
On Monday, 671 companies achieved new lows for the year.
On Monday, 524 stocks hit new 52-week lows.
During the morning session on Thursday, 152 stocks hit new 52-week lows.
Gainers Flanigan's Enterprises, Inc. (NYSE: BDL) shares surged 40.6% to close at $34.90 on Tu
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 28.4% to $10.17 following reports indic
Gainers
Gainers
Stocks That Hit 52-Week Lows On Monday
108 Biggest Movers From Yesterday
58 Biggest Movers From Yesterday